ATE535514T1 - Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten - Google Patents
Carboxamid-spirohydantoin-cgrp-rezeptor- antagonistenInfo
- Publication number
- ATE535514T1 ATE535514T1 AT04719234T AT04719234T ATE535514T1 AT E535514 T1 ATE535514 T1 AT E535514T1 AT 04719234 T AT04719234 T AT 04719234T AT 04719234 T AT04719234 T AT 04719234T AT E535514 T1 ATE535514 T1 AT E535514T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- cgrp receptor
- carboxamide
- compounds
- spirohydantoin cgrp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45560803P | 2003-03-14 | 2003-03-14 | |
| PCT/US2004/007226 WO2004082602A2 (en) | 2003-03-14 | 2004-03-10 | Carboxamide spirohydantoin cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535514T1 true ATE535514T1 (de) | 2011-12-15 |
Family
ID=33030029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04719234T ATE535514T1 (de) | 2003-03-14 | 2004-03-10 | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7288559B2 (de) |
| EP (1) | EP1613368B1 (de) |
| JP (1) | JP4690313B2 (de) |
| AT (1) | ATE535514T1 (de) |
| AU (1) | AU2004222378B2 (de) |
| CA (1) | CA2518830A1 (de) |
| WO (1) | WO2004082602A2 (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| WO2004087649A2 (en) * | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| US7569578B2 (en) | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| WO2006029153A2 (en) * | 2004-09-08 | 2006-03-16 | Merck & Co., Inc. | Monocyclic anilide spirolactam cgrp receptor antagonists |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| RS57194B1 (sr) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals Int Gmbh | Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje |
| US7851464B2 (en) | 2005-11-18 | 2010-12-14 | Merck Sharp & Dohme Corp. | Spirolactam aryl CGRP receptor antagonists |
| JP2009515971A (ja) * | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロヒダントインアリールｃｇｒｐ受容体アンタゴニスト |
| ES2368456T3 (es) | 2006-05-02 | 2011-11-17 | Bristol-Myers Squibb Company | Compuestos restringidos como antagonistas del receptor de cgrp. |
| US7470680B2 (en) * | 2006-05-03 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| CA2658573A1 (en) * | 2006-07-21 | 2008-01-24 | Vertex Pharmaceuticals Incorporated | Cgrp receptor antagonists |
| WO2008073251A1 (en) * | 2006-12-08 | 2008-06-19 | Merck & Co., Inc. | Constrained spirocyclic compounds as cgrp receptor antagonists |
| MX2010009722A (es) | 2008-03-04 | 2010-09-30 | Pfizer Ltd | Procedimiento de tratamiento del dolor cronico. |
| TW201026691A (en) | 2008-10-07 | 2010-07-16 | Schering Corp | Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators |
| TW201026672A (en) * | 2008-10-07 | 2010-07-16 | Schering Corp | Spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators |
| EP3165236B1 (de) | 2009-08-28 | 2022-03-16 | Teva Pharmaceuticals International GmbH | Verfahren zur behandlung von eingeweideschmerz mittels verabreichung von antagonistischen antikörpern gegen calcitoningen-assoziiertes peptid |
| EP2637656B1 (de) * | 2010-11-12 | 2016-12-14 | Merck Sharp & Dohme Corp. | N-Piperidinon-indan-carboxamide als CGRP-Rezeptor-Antagonisten |
| TWI522355B (zh) | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| EP2685826B1 (de) * | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinoncarboxamid-spirohydantoin-cgrp-rezeptorantagonisten |
| NZ732875A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| LT3495392T (lt) | 2011-05-20 | 2021-09-27 | H. Lundbeck A/S | Anti-cgrp kompozicijos ir jų panaudojimas |
| KR101965461B1 (ko) | 2011-05-20 | 2019-04-04 | 앨더바이오 홀딩스 엘엘씨 | 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도 |
| WO2013169565A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP2846799B1 (de) * | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam-cgrp-rezeptorantagonisten |
| WO2015119848A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| JP6568099B2 (ja) | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| FR3030521B1 (fr) * | 2014-12-23 | 2019-07-26 | Galderma Research & Development | Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique |
| WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| BR112019005823A2 (pt) | 2016-09-23 | 2019-06-25 | Teva Pharmaceuticals Int Gmbh | tratamento para enxaqueca refratária |
| ES2912295T3 (es) | 2016-12-09 | 2022-05-25 | Denali Therapeutics Inc | Compuestos útiles como inhibidores de RIPK1 |
| EP3366286A1 (de) | 2017-02-22 | 2018-08-29 | Johannes Keller | Verbindungen zur behandlung von sepsis |
| WO2018187667A1 (en) * | 2017-04-06 | 2018-10-11 | Alliance For Sustainable Energy, Llc | Renewable polymers and resins and methods of making the same |
| WO2020146527A1 (en) | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
| WO2022140537A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4772632A (en) * | 1987-02-24 | 1988-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Antineoplastic, system - L specific amino acid nitrogen mustards |
| FR2709306B1 (fr) * | 1993-07-20 | 1995-10-20 | Adir | Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| AUPN449295A0 (en) * | 1995-07-28 | 1995-08-24 | Inner And Eastern Health Care Network, The | Radioprotectors |
| JP3449084B2 (ja) * | 1995-12-25 | 2003-09-22 | 富士レビオ株式会社 | ヒダントイン誘導体 |
-
2004
- 2004-03-10 US US10/546,889 patent/US7288559B2/en not_active Expired - Lifetime
- 2004-03-10 CA CA002518830A patent/CA2518830A1/en not_active Abandoned
- 2004-03-10 AT AT04719234T patent/ATE535514T1/de active
- 2004-03-10 JP JP2006507015A patent/JP4690313B2/ja not_active Expired - Fee Related
- 2004-03-10 AU AU2004222378A patent/AU2004222378B2/en not_active Ceased
- 2004-03-10 EP EP04719234A patent/EP1613368B1/de not_active Expired - Lifetime
- 2004-03-10 WO PCT/US2004/007226 patent/WO2004082602A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP4690313B2 (ja) | 2011-06-01 |
| US7288559B2 (en) | 2007-10-30 |
| CA2518830A1 (en) | 2004-09-30 |
| WO2004082602A3 (en) | 2005-11-17 |
| EP1613368A2 (de) | 2006-01-11 |
| AU2004222378A1 (en) | 2004-09-30 |
| JP2006520381A (ja) | 2006-09-07 |
| WO2004082602A2 (en) | 2004-09-30 |
| US20070111982A1 (en) | 2007-05-17 |
| EP1613368A4 (de) | 2008-06-18 |
| AU2004222378B2 (en) | 2008-08-14 |
| EP1613368B1 (de) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535514T1 (de) | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten | |
| ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| EP1606286A4 (de) | Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten | |
| ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| ATE411323T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE464305T1 (de) | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE463245T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| ATE537153T1 (de) | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors | |
| WO2005013894A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| ATE518852T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| DE602007008434D1 (de) | Rezeptoren | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten |